GPAT: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -38% 1 243 Improvement, Studies, Patients Relative Risk Hospitalization -38% 1 243 RCTs -38% 1 243 Early -38% 1 243 GPAT for COVID-19 c19early.org May 2026 FavorsGPAT Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ An (RCT) -38% 1.38 [1.05-1.81] hosp. 128 (n) 115 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.019 Early treatment -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk All studies -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk 1 GPAT COVID-19 study c19early.org May 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.019 Effect extraction pre-specified(most serious outcome) Favors GPAT Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ An (RCT) -38% 1.38 [1.05-1.81] hosp. 128 (n) 115 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.019 Early treatment -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk All studies -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk 1 GPAT COVID-19 hospitalization result c19early.org May 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.019 Favors GPAT Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ An (RCT) -35% 1.35 [1.03-1.77] no recov. 128 (n) 115 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.028 Early treatment -35% 1.35 [1.03-1.77] 128 (n) 115 (n) 35% higher risk All studies -35% 1.35 [1.03-1.77] 128 (n) 115 (n) 35% higher risk 1 GPAT COVID-19 recovery result c19early.org May 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.028 Favors GPAT Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ An (RCT) -38% 1.38 [1.05-1.81] hosp. 128 (n) 115 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.019 Early treatment -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk All studies -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk 1 GPAT COVID-19 Randomized Controlled Trial c19early.org May 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.019 Effect extraction pre-specified(most serious outcome) Favors GPAT Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ An (RCT) -38% 1.38 [1.05-1.81] hosp. 128 (n) 115 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.019 Early treatment -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk All studies -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk 1 GPAT COVID-19 peer reviewed studies c19early.org May 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.019 Effect extraction pre-specified(most serious outcome) Favors GPAT Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ An (RCT) -38% 1.38 [1.05-1.81] hosp. 128 (n) 115 (n) Improvement, RR [CI] Treatment Control An (RCT) -35% 1.35 [1.03-1.77] no recov. 128 (n) 115 (n) GPAT COVID-19 outcomes c19early.org May 2026 Favors GPAT Favors control